SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol “NAYA” at the market open on Tuesday, October 22, 2024.
Invo Bioscience (NASDAQ: INVO) stock is surging today after the company released its earnings report for the fourth quarter of 2023, which showed a $2 million net loss for the healthcare services fertility company.
One of the most impressive movers making the most noise in today's session has to be INVO Bioscience (NASDAQ: INVO ). Shares of INVO stock have more than tripled in today's session, surging well more than 325% at the time of writing.
INVO Bioscience, Inc. (NASDAQ:INVO ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Robert Blum - Investor Relations Steve Shum - Chief Executive Officer Mike Campbell - Chief Operating and Vice President, Business Development Andrea Goren - Chief Financial Officer Operator Good afternoon. And welcome, to the INVO Bioscience Second Quarter Fiscal Year 2023 Financial Results Conference Call.
INVO Bioscience (NASDAQ: INVO ) stock is on the rise Monday after the company announced a public share offering on Friday. According to a Securities and Exchange Commission (SEC) filing from INVO Bioscience, certain investors may offer up to 6,241,493 shares of INVO stock.
INVO Bioscience, Inc. (NASDAQ:INVO ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Robert Blum - Lytham Partners Steve Shum - CEO Mike Campbell - Chief Operating Officer and VP of Business Development Andrea Goren - Chief Financial Officer Conference Call Participants Joanne Lee - Maxim Group Rodney Baber - Paulson Investments Operator Good day. And welcome to the INVO First Quarter 2023 Financial Results Conference Call.
INVO Bioscience, Inc. (NASDAQ:INVO) Q4 2022 Earnings Conference Call April 17, 2023 4:30 PM ET
INVO Bioscience announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to buy 3,680,000 shares of common stock. The post INVO Bioscience Announces Pricing of $3 Million Registered Direct Offering Priced At-The-Market appeared first on Pulse 2.0.